Wollin, L; Distler, JHW; Denton, CP; Gahlemann, M; (2019) Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis–associated interstitial lung disease. Journal of Scleroderma and Related Disorders 10.1177/2397198319841842. (In press).